18:10 EDT Nektar (NKTR) up 12% to 91c after Oppenheimer upgrade with $6 target Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses.

Nektar Therapeutics (NKTR) came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s rezpegaldesleukin in atopic dermatitis – AD ...

Nektar Therapeutics has a 12 month low of $0.65 and a 12 month high of $1.93. Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th.

4 analysts have expressed a variety of opinions on Nektar Therapeutics NKTR over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a ...

Lilly partnered with Nektar on the drug in 2017, paying $150 million upfront with another $250 million at the back end in development and regulatory milestones. It has agreed to fund 75% of the ...

Nektar shed 70% of its workforce as a result and refocused its R&D on NKTR-358, an IL-2 conjugate regulatory T cell stimulator for inflammatory conditions like lupus and atopic dermatitis ...

SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research ...

Nektar Therapeutics (NKTR) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.